Abstract
Cinoxacin, a new synthetic antibacterial agent with in vitro activity against all species of Enterobacteriaceae, was used in the treatment of urinary tract infections in 20 patients. The dose of cinoxacin was 250 mg orally every 6 h for 10 days. The etiological agents were Escherichia coli in fifteen, Klebsiella-Enterobacter in five, Proteus mirabilis in two, and Providencia in one. The minimal inhibitory concentration for these organisms ranged from 2 to 64 μg/ml. Eleven of the 20 patients had renal involvement by defined criteria, whereas the remaining nine were considered to have bladder bacilluria. The initial strain was eradicated during and immediately after treatment in 19 of 20 cases. At 6 weeks, 65% had sterile urine. Bactericidal urine levels of cinoxacin were obtained in all patients. No significant hematological, renal, hepatic, or gastroenterologic toxicity was noted. Cinoxacin appears to be a safe and useful drug in the treatment of urinary tract infections caused by Enterobacteriaceae.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Giamarellou H., Jackson G. G. Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother. 1975 May;7(5):688–692. doi: 10.1128/aac.7.5.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lumish R. M., Norden C. W. Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother. 1975 Feb;7(2):159–163. doi: 10.1128/aac.7.2.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stamey T. A., Fair W. R., Timothy M. M., Millar M. A., Mihara G., Lowery Y. C. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974 Nov 28;291(22):1159–1163. doi: 10.1056/NEJM197411282912204. [DOI] [PubMed] [Google Scholar]
- Wick W. E., Preston D. A., White W. A., Gordee R. S. Compound 64716, a new synthetic antibacterial agent. Antimicrob Agents Chemother. 1973 Oct;4(4):415–420. doi: 10.1128/aac.4.4.415. [DOI] [PMC free article] [PubMed] [Google Scholar]